Diseases / Thrombosis
Thrombosis
DiseaseThrombosis refers to formation of blood clots within blood vessels, which can obstruct blood flow and cause major complications such as pulmonary embolism, stroke, or organ ischemia. Venous thromboembolism is a major preventable cause of morbidity and mortality.
- Trials
- 951
- Recruiting
- 109
- Completed
- 535
- With results
- 127
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Temporarily not available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 5 | — | — | — | — | 6 |
| Phase 1 | 2 | 1 | — | 1 | 42 | 2 | — | 3 | — | 51 |
| Phase 1/2 | 2 | — | — | — | 7 | 1 | 2 | — | — | 12 |
| Phase 2 | 4 | 1 | 1 | 1 | 38 | 10 | — | 8 | — | 63 |
| Phase 2/3 | 3 | — | — | — | 7 | 2 | — | 1 | — | 13 |
| Phase 3 | 9 | 3 | — | — | 53 | 14 | 2 | 13 | — | 94 |
| Phase 4 | 7 | 3 | — | 2 | 66 | 10 | 3 | 16 | — | 107 |
| Not applicable | 18 | 9 | 1 | 3 | 114 | 13 | 6 | 34 | — | 198 |
| Unknown | 63 | 18 | — | 10 | 203 | 10 | 12 | 90 | 1 | 407 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | 6 | 51 | 12 | 63 | 13 | 94 | 107 | 198 | 407 | 951 |
| Hemorrhage | — | 3 | — | 9 | 1 | 9 | 17 | 10 | 48 | 97 |
| Venous Thrombosis | 1 | 3 | — | 7 | 1 | 15 | 10 | 17 | 35 | 89 |
| Pulmonary Embolism | 1 | 1 | — | 5 | — | 7 | 6 | 14 | 33 | 67 |
| Stroke | 1 | 2 | 1 | 9 | 1 | 9 | 8 | 9 | 22 | 62 |
| Venous Thromboembolism | 2 | — | — | 4 | 3 | 12 | 8 | 5 | 23 | 57 |
| Cardiovascular Diseases | — | 2 | — | 3 | — | 6 | 8 | 7 | 30 | 56 |
| Inflammation | — | 3 | 1 | 4 | 1 | 1 | 8 | 12 | 20 | 50 |
| Thromboembolism | 1 | 1 | — | 1 | — | 10 | 11 | 6 | 18 | 48 |
| Ischemic Stroke | 1 | — | 1 | 8 | — | 3 | 7 | 10 | 17 | 47 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Bristol-Myers Squibb | 19 | 0 |
| 2 | HemoSonics LLC | 19 | 0 |
| 3 | Assistance Publique - Hôpitaux de Paris | 11 | 4 |
| 4 | University of Edinburgh | 11 | 0 |
| 5 | Bayer | 10 | 1 |
| 6 | National Heart, Lung, and Blood Institute (NHLBI) | 10 | 2 |
| 7 | ARCA Biopharma, Inc. | 9 | 5 |
| 8 | Brigham and Women's Hospital | 9 | 2 |
| 9 | University Hospital, Bordeaux | 8 | 1 |
| 10 | Assiut University | 7 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Rivaroxaban | 45 |
| 2 | Aspirin | 43 |
| 3 | Warfarin | 34 |
| 4 | Enoxaparin | 33 |
| 5 | Clopidogrel | 32 |
| 6 | apixaban | 28 |
| 7 | Blood Specimen Collection | 26 |
| 8 | Heparin | 20 |
| 9 | Ticagrelor | 18 |
| 10 | edoxaban | 14 |
Evidence
- Results reported
- 23.7%127 of 535 completed
- Published
- 16.3%87 of 535 completed
- Primary endpoint met
- 44.4%40 of 90 analyses
- Median months to report
- 15
Documents disclosed
Trial profile
- Median enrollment
- 102
- Median duration
- 29months
- Countries
- 78
- Study sites
- 6566
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 25
- Phase 1
- 30
- Phase 1/2
- 37
- Phase 2
- 60
- Phase 2/3
- 100
- Phase 3
- 254
- Phase 4
- 100
- Not applicable
- 60
- Unknown
- 160
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 41 |
| 2 | Paris | France | 40 |
| 3 | New York | United States | 38 |
| 4 | Houston | United States | 34 |
| 5 | Baltimore | United States | 33 |
| 6 | Philadelphia | United States | 33 |
| 7 | Columbus | United States | 32 |
| 8 | Toronto | Canada | 31 |
| 9 | Barcelona | Spain | 30 |
| 10 | São Paulo | Brazil | 29 |
Terminations
- Terminated
- 62
- Withdrawn
- 25
- Stopped for recruitment
- 2.4%23 of 951 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06318754 Withdrawn | Withdrawn | PI is leaving UMB institution. IRB approval was never obtained and the study was never open. | 2027-03-31 |
| NCT06975969 Withdrawn | Withdrawn | No participants enrolled. | 2026-02-20 |
| NCT06879509 Withdrawn | Withdrawn | No participants enrolled | 2026-02-04 |
| NCT04855370 Withdrawn | Withdrawn | Study device no longer available | 2025-12-31 |
| NCT03077269 Terminated | Terminated | Study terminated due to resource constraints and inadequate funding. | 2025-05-19 |
| NCT06415968 Terminated | Terminated | difficulty of inclusion, PI decision | 2025-02-11 |
| NCT02881554 Terminated | Terminated | Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.) | 2025-02-09 |
| NCT05561244 Terminated | Terminated | In the absence of patients meeting the selection criteria, the study was prematurely terminated. The average number of patients on VKAs per EHPAD has fallen sharply because of the development of direct oral anticoagulants and the Covid crisis. | 2024-12-13 |
| NCT05554055 Withdrawn | Withdrawn | The AXAES study was stopped mainly for logistical and organizational reasons. The machine needed to carry out the examinations was no longer available, making it impossible to continue the study. | 2024-11-30 |
| NCT04684212 Withdrawn | Withdrawn | Lack of Funding | 2024-07-11 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: